Abstract 1404P
Background
Combination of anti-PD1 inhibitor with chemoradiotherapy (CRT) has been shown to improve the survival of patients with locally advanced esophageal squamous cell carcinoma (ESCC). This study specifically aims to identify circulating cytokines as biomarkers for predicting treatment response, survival, and immune-related toxicities.
Methods
Patients with locally advanced ESCC from two phase II clinical trials (EC-CRT-001 and NEOCRTEC1901) were pooled for analysis. All patients received CRT in combination with toripalimab, an anti-PD1 inhibitor. We longitudinally profiled 19 cytokines in the plasma before (pre), during, and after (post) CRT. The associations between cytokine levels and treatment response or immune-related toxicity were examined using the Wilcoxon test. Their correlations with overall survival (OS) and progression-free survival (PFS) were assessed through univariate and multivariate Cox analyses.
Results
A total of 81 patients were included, and 243 plasma samples were analyzed. Multivariate analyses indicated that pre-treatment levels of IL-8 and post-treatment levels of Granzyme B were independent prognostic markers for OS (p<0.05). Post-CRT levels of IL-10 were identified as independent prognostic markers for PFS (p<0.05). Subgroup analyses revealed correlations between pre- and during-CRT levels of IL-8, and post-CRT levels of IL-13 and IL-10 with a complete clinical response in the EC-CRT-001 group. Additionally, pre-CRT IL-8 and post-CRT CCL5 levels were associated with immune-related toxicities.
Conclusions
Circulating cytokines, particularly IL-8, serve as significant biomarkers for predicting response, survival, and immune-related toxicities in locally advanced ESCC patients undergoing combined chemoradiotherapy and toripalimab treatment.
Clinical trial identification
NCT04005170; NCT04006041.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1164P - The influence of neoadjuvant radiotherapy on surgical management and prognostic outcomes in locally advanced rectal neuroendocrine carcinoma
Presenter: Weiran Xu
Session: Poster session 17
1165P - The significance and indications for lymphadenectomy in pancreatic neuroendocrine neoplasms
Presenter: Yosuke Uematsu
Session: Poster session 17
1166P - 21-day modified CAPTEM protocol is effective and safe for patients with advanced well-differentiated grade 1/2 pancreatic neuroendocrine tumors
Presenter: Nomi Bezalel Engelberg
Session: Poster session 17
1167P - Outcomes of local and systemic treatment in primary hepatic neuroendocrine neoplasms (PHNEN)
Presenter: Leonidas Apostolidis
Session: Poster session 17
1169P - Clustering of patients with lung neuroendocrine neoplasms using machine learning and its association with survival: A population based study from the U.S. SEER database
Presenter: Mohamed Mortagy
Session: Poster session 17
1170P - Convergent and divergent determinants of heterogeneity, biomarkers, and plasticity in thoracic and prostate neuroendocrine tumors
Presenter: Triparna Sen
Session: Poster session 17
Resources:
Abstract
1403P - A phase II study of tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: Long-term follow-up outcomes of TD-NICE
Presenter: Tao Jiang
Session: Poster session 17
1405P - Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for esophageal squamous cell carcinoma (EC-CRT-001 phase II trial)
Presenter: Ruixi Wang
Session: Poster session 17
Resources:
Abstract
1406P - Interim response evaluation from a phase II study of capecitabine, oxaliplatin, and anti-PD-1 in dMMR esophagogastric cancer (AuspiCiOus trial)
Presenter: Joris Bos
Session: Poster session 17